Editorial: Interaction between hyaluronic acid and its receptors (CD44, RHAMM) regulates the activity of inflammation and cancer

Frontiers in Immunology

Volumn 7, Issue FEB, 2016, Pages

  Naor, David ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cancer; CD44; Hyaluronan; Inflammation; RHAMM

Indexed keywords

GLYCOSAMINOGLYCAN; HERMES ANTIGEN; HYALURONIC ACID; HYALURONIC ACID BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOID DIFFERENTIATION FACTOR 88;

APOPTOSIS; CELL ADHESION; CELL HOMING; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; EDITORIAL; EPITHELIAL MESENCHYMAL TRANSITION; EXTRAVASATION; HEMATOPOIESIS; HUMAN; INFLAMMATION; LYMPHOCYTE ACTIVATION; NEOPLASM; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SENSITIVITY ANALYSIS; UPREGULATION;

EID: 84962552024     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00039     Document Type: Editorial

References (12)

1. Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev (2011) 91(1):221-64. doi: 10.1152/physrev.00052.2009.
2. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res (1997) 71:241-319. doi:10.1016/S0065-230X(08)60101-3.
3. Tian X, Azpurua J, Hine C, Vaidya A, Myakishev-Rempel M, Ablaeva J, et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature (2013) 499(7458):346-9. doi:10.1038/nature12234.
4. Hill DR, Kessler SP, Rho HK, Cowman MK, delaMotte CA. Specific-sized hyaluronan fragments promote expression of human β-defensin 2 in intestinal epithelium. J Biol Chem (2012) 287:30610-24. doi:10.1074/jbc.M112.356238.
5. Tolg C, Telmer P, Turley E. Specific sizes of hyaluronan oligosaccharides stimulate fibroblast migrationan and excisional wound repair. PLoS One (2014) 9(2):e88479. doi:10.1371/journal.pone.0088479.
6. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci (2002) 39(6):527-79. doi:10.1080/10408360290795574.
7. Xu H, Tian Y, Yuan X, Wu H, Liu Q, Pestell RG, et al. The role of CD44 in epithelial-mesenchymal transition and cancer development. Onco Targets Ther (2015) 16(8):3783-92. doi:10.2147/OTT.S95470.
8. Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res (2006) 12(20 Pt 1):6064-72. doi:10.1158/1078-0432.CCR-06-0910.
9. Zhang S, Chang MC, Zylka D, Turley S, Harrison R, Turley EA. The hyaluronan receptor RHAMM regulates extracellular-regulated kinase. J Biol Chem (1998) 273:11342-8. doi:10.1074/jbc.273.18.11342.
10. Yang B, Yang BL, Savani RC, Turley EA. Identification of a common hyaluro-nan binding motif in the hyaluronan binding protein sRHAMM, CD44 and linkprotein. EMBO J (1994) 13:286-96.
11. Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, et al. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A (2004) 101(52):18081-6. doi:10.1073/pnas.0407378102.
12. Assayag-Asherie N, Sever D, Bogdani M, Johnson P, Weiss T, Ginzberg A, et al. Can CD44 be a mediator of cell destruction? The challenge of type 1 diabetes. PLoS One (2015) 10(12):e0143589. doi:10.1371/journal.pone.0143589.